Behavioral and histopathological consequences of paraquat intoxication in mice: Effects of α-synuclein over-expression

Synapse

Volumn 61, Issue 12, 2007, Pages 991-1001

  Fernagut, P O ^a   Hutson, C B ^a   Fleming, S M ^a   Tetreaut, N A ^a   Salcedo, J ^a   Masliah, E ^b   Chesselet, Marie Françoise ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Locus coeruleus; Mice; Parkinson's disease; Pesticide; Striatum; Substantia nigra

Indexed keywords

ALPHA SYNUCLEIN; BRAIN PROTEIN; PARAQUAT; TYROSINE 3 MONOOXYGENASE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; GENE OVEREXPRESSION; HISTOPATHOLOGY; LOCUS CERULEUS; MOUSE; NONHUMAN; PARAQUAT POISONING; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; SUBSTANTIA NIGRA;

ALPHA-SYNUCLEIN; ANALYSIS OF VARIANCE; ANIMALS; BEHAVIOR, ANIMAL; CELL COUNT; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; HUMANS; LOCUS COERULEUS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MOTOR ACTIVITY; NEURONS; NEUROTOXICITY SYNDROMES; PARAQUAT; PSYCHOMOTOR PERFORMANCE; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

EID: 37249011444     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.20456     Document Type: Article

References (55)

1. Arrasate M, Mitra S, Schweitzer ES, Segal MR, Finkbeiner S. 2004. Inclusion body formation reduces levels of mutant Huntingtin and the risk of neuronal death. Nature 431:805-810.
2. Bonneh-Barkay D, Langston WJ, Di Monte DA. 2005. Toxicity of redox cycling pesticides in primary mesencephalic cultures. Antioxid Redox Signal 7:649-653.
3. Bordelon YM, Chesselet MF. 1999. Early effects of intrastriatal injections of quinolinic acid on microtubule-associated protein-2 and neuropeptides in rat basal ganglia. Neuroscience 93:843-853.
4. Braak H, Del Tredici K, Rub U, de Vos RA, Steur ENJ, Braak E. 2003. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24:197-211.
5. Braak H, Bohl JR, Muller CM, Rub U, de Vos RA, Del Tredici K. 2006. Stanley Fahn Lecture 2005: The staging procedure for the inclusion body pathology associated with sporadic Parkinson's disease reconsidered. Mov Disord 21:2042-2051.
6. Chen L, Feany MB. 2005. α-Synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. Nat Neurosci 8:657-663.
7. Chen L, Thiruchelvam MJ, Madura K, Richfield EK. 2006. Proteasome dysfunction in aged human α-synuclein transgenic mice. Neurobiol Dis 23:120-126.
8. Conway KA, Rochet JC, Bieganski RM, Lansbury PT Jr. 2001. Kinetic stabilization of the α-synuclein protofibril by a dopamine-α- synuclein adduct. Science 294:1346-1349.
9. Di Monte DA, Lavasani M, Manning-Bog AB. 2002. Environmental factors in Parkinson's disease. Neurotoxicology 23:487-502.
10. Farrer M, Maraganore DM, Lockhart P, Singleton A, Lesnick TG, de Andrade M, West A, de Silva R, Hardy J, Hernandez D. 2001. α-Synuclein gene haplotypes are associated with Parkinson's disease. Hum Mol Genet 10:1847-1851.
11. Fearnley JM, Lees AJ. 1991. Ageing and Parkinson's disease: Substantia nigra regional selectivity. Brain 114 (Part 5):2283-2301.
12. Fernagut PO, Chesselet MF. 2004. α-Synuclein and transgenic mouse models. Neurobiol Dis 17:123-130.
13. Finkelstein DI, Stanic D, Parish CL, Tomas D, Dickson K, Horne MK. 2000. Axonal sprouting following lesions of the rat substantia nigra. Neuroscience 97:99-112.
14. Fleming SM, Salcedo J, Fernagut PO, Rockenstein E, Masliah E, Levine MS, Chesselet MF. 2004. Early and progressive sensorimotor anomalies in mice overexpressing wild-type human α-synuclein. J Neurosci 24:9434-9440.
15. Fleming SM, Salcedo J, Hutson CB, Rockenstein E, Masliah E, Levine MS, Chesselet MF. 2006a. Behavioral effects of dopaminergic agonists in transgenic mice overexpressing human wildtype α-synuclein. Neuroscience 142:1245-1253.
16. Fleming SM, Tetreault N, Masliah E, Chesselet MF. 2006b.Alterations in olfactory function in transgenic mice overexpressing human wild-type α-synuclein. In: 36th Annual Meeting of the Society for Neuroscience, Altanta, October 14-18.
17. German DC, Dubach M, Askari S, Speciale SG, Bowden DM. 1988. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonian syndrome in Macaca fascicularis: Which midbrain dopaminergic neurons are lost? Neuroscience 24:161-174.
18. German DC, Manaye KF, Sonsalla PK, Brooks BA. 1992. Midbrain dopaminergic cell loss in Parkinson's disease and MPTP-induced Parkinsonism: Sparing of calbindin-D28k-containing cells. Ann N Y Acad Sci 648:42-62.
19. Graybiel AM, Ohta K, Roffler-Tarlov S. 1990. Patterns of cell and fiber vulnerability in the mesostriatal system of the mutant mouse weaver. I. Gradients and compartments. J Neurosci 10:720-733.
20. Greenamyre JT, Hastings TG. 2004. Biomedicine. Parkinson's - Divergent causes, convergent mechanisms. Science 304:1120-1122.
21. Greene JG, Dingledine R, Greenamyre JT. 2005. Gene expression profiling of rat midbrain dopamine neurons: Implications for selective vulnerability in Parkinsonism. Neurobiol Dis 18:19-31.
22. Guyenet PG, Aghajanian GK. 1978. Antidromic identification of dopaminergic and other output neurons of the rat substantia nigra. Brain Res 150:69-84.
23. Halliday GM, Li YW, Blumbergs PC, Joh TH, Cotton RG, Howe PR, Blessing WW, Geffen LB. 1990. Neuropathology of immunohistochemically identified brainstem neurons in Parkinson's disease. Ann Neurol 27:373-385.
24. Halliday GM, Del Tredici K, Braak H. 2006. Critical appraisal of brain pathology staging related to presymptomatic and symptomatic cases of sporadic Parkinson's disease. J Neural Transm Suppl:99-103.
25. Hertzman C, Wiens M, Bowering D, Snow B, Calne D. 1990. Parkinson's disease: A case-control study of occupational and environmental risk factors. Am J Ind Med 17:349-355.
26. Holzmann C, Kruger R, Saecker AM, Schmitt I, Schols L, Berger K, Riess O. 2003. Polymorphisms of the α-synuclein promoter: Expression analyses and association studies in Parkinson's disease. J Neural Transm 110:67-76.
27. Hwang DY, Fleming SM, Ardayfio P, Moran-Gates T, Kim H, Tarazi FI, Chesselet MF, Kim KS. 2005. 3,4-Dihydroxyphenylalanine reverses the motor deficits in Pitx3-deficient aphakia mice: Behavioral characterization of a novel genetic model of Parkinson's disease. J Neurosci 25:2132-2137.
28. Jellinger KA. 1991. Pathology of Parkinson's disease. Changes other than the nigrostriatal pathway. Mol Chem Neuropathol 14:153-197.
29. Lee VM, Trojanowski JQ. 2006. Mechanisms of Parkinson's disease linked to pathological α-synuclein: New targets for drug discovery. Neuron 52:33-38.
30. Leng Y, Chuang DM. 2006. Endogenous α-synuclein is induced by valproic acid through histone deacetylase inhibition and participates in neuroprotection against glutamate-induced excitotoxicity. J Neurosci 26:7502-7512.
31. Liang CL, Sinton CM, Sonsalla PK, German DC. 1996. Midbrain dopaminergic neurons in the mouse that contain calbindin-D28k exhibit reduced vulnerability to MPTP-induced neurodegeneration. Neurodegeneration 5:313-318.
32. Liou HH, Tsai MC, Chen CJ, Jeng JS, Chang YC, Chen SY, Chen RC. 1997. Environmental risk factors and Parkinson's disease: A case-control study in Taiwan. Neurology 48:1583-1588.
33. Manning-Bog AB, McCormack AL, Li J, Uversky VN, Fink AL, Di Monte DA. 2002. The herbicide paraquat causes up-regulation and aggregation of α-synuclein in mice: Paraquat and α-synuclein. J Biol Chem 277:1641-1644.
34. Manning-Bog AB, McCormack AL, Purisai MG, Bolin LM, Di Monte DA. 2003. α-Synuclein overexpression protects against paraquat-induced neurodegeneration. J Neurosci 23:3095-3099.
35. Matsuura K, Kabuto H, Makino H, Ogawa N. 1997. Pole test is a useful method for evaluating the mouse movement disorder caused by striatal dopamine depletion. J Neurosci Methods 73:45-48.
36. McCormack AL, Thiruchelvam M, Manning-Bog AB, Thiffault C, Langston JW, Cory-Slechta DA, Di Monte DA. 2002. Environmental risk factors and Parkinson's disease: Selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat. Neurobiol Dis 10:119-127.
37. McCormack AL, Atienza JG, Johnston LC, Andersen JK, Vu S, Di Monte DA. 2005. Role of oxidative stress in paraquat-induced dopaminergic cell degeneration. J Neurochem 93:1030-1037.
38. McCormack AL, Atienza JG, Langston JW, Di Monte DA. 2006. Decreased susceptibility to oxidative stress underlies the resistance of specific dopaminergic cell populations to paraquat-induced degeneration. Neuroscience 141:929-937.
39. Norris EH, Uryu K, Leight S, Giasson BI, Trojanowski JQ, Lee VM. 2007. Pesticide exposure exacerbates α-synucleinopathy in an A53T transgenic mouse model. Am J Pathol 170:658-666.
40. Pals P, Lincoln S, Manning J, Heckman M, Skipper L, Hulihan M, Van den Broeck M, De Pooter T, Cras P, Crook J, Van Broeckhoven C, Farrer MJ. 2004. α-Synuclein promoter confers susceptibility to Parkinson's disease. Ann Neurol 56:591-595.
41. Purisai MG, McCormack AL, Cumine S, Li J, Isla MZ, Di Monte DA. 2007. Microglial activation as a priming event leading to paraquat-induced dopaminergic cell degeneration. Neurobiol Dis 25:392-400.
42. Rockenstein E, Mallory M, Hashimoto M, Song D, Shults CW, Lang I, Masliah E. 2002. Differential neuropathological alterations in transgenic mice expressing α-synuclein from the platelet-derived growth factor and Thy-1 promoters. J Neurosci Res 68:568-578.
43. Sanghera MK, Manaye K, McMahon A, Sonsalla PK, German DC. 1997. Dopamine transporter mRNA levels are high in midbrain neurons vulnerable to MPTP. Neuroreport 8:3327-3331.
44. Saudou F, Finkbeiner S, Devys D, Greenberg ME. 1998. Huntington acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 95:55-66.
45. Semchuk KM, Love EJ, Lee RG. 1992. Parkinson's disease and exposure to agricultural work and pesticide chemicals. Neurology 42:1328-1335.
46. Spillantini MG, Goedert M. 2000. The α-synucleinopathies: Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. Ann N Y Acad Sci 920:16-27.
47. Thiruchelvam MJ, Powers JM, Cory-Slechta DA, Richfield EK. 2004. Risk factors for dopaminergic neuron loss in human α-synuclein transgenic mice. Eur J Neurosci 19:845-854.
48. Uversky VN, Li J, Fink AL. 2001. Pesticides directly accelerate the rate of α-synuclein fibril formation: A possible factor in Parkinson's disease. FEBS Lett 500:105-108.
49. Uversky VN, Yamin G, Munishkina LA, Karymov MA, Millett IS, Doniach S, Lyubchenko YL, Fink AL. 2005. Effects of nitration on the structure and aggregation of α-synuclein. Brain Res Mol Brain Res 134:84-102.
50. van der Putten H, Wiederhold KH, Probst A, Barbieri S, Mistl C, Danner S, Kauffmann S, Hofele K, Spooren WP, Ruegg MA, Lin S, Caroni P, Sommer B, Tolnay M, Bilbe G. 2000. Neuropathology in mice expressing human α-synuclein. J Neurosci 20:6021-6029.
51. Watson JB, Chesselet MF, Masliah E, Levine MS. 2005. Enhancement of striatal synaptic plasticity in α-synuclein overexpressing mice. In: 35th Annual Meeting of the Society for Neuroscience, Washington, DC, November 12-16.
52. West MJ. 2002. Design-based stereological methods for counting neurons. Prog Brain Res 135:43-51.
53. West MJ, Slomianka L, Gundersen HJ. 1991. Unbiased stereological estimation of the total number of neurons in thesubdivisions of the rat hippocampus using the optical fractionator. Anat Rec 231:482-497.
54. Wu N, Cepeda C, Masliah E, Levine MS. 2005.Abnormal glutamate and dopamine receptor function in the striatum of α-synuclein overexpressing mice. In: 35th Annual Meeting of the Society for Neuroscience, Washington, DC, November 12-16.
55. Zigmond MJ, Acheson AL, Stachowiak MK, Strieker EM. 1984. Neurochemical compensation after nigrostriatal bundle injury in an animal model of preclinical Parkinsonism. Arch Neurol 41:856-861.